CK
Highly rated in
32
conditions
Highly rated in
32
conditions
Check Dr. Craig M. Kessler's experience treating your condition:
About Dr. Craig M. Kessler

Craig Kessler is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Kessler has been practicing medicine for over 49 years and is highly rated in 32 conditions, according to our data. His top areas of expertise are Hemophilia A, Blood Clots, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in District of Columbia. Kessler is currently accepting new patients.

His clinical research consists of co-authoring 146 peer reviewed articles and participating in 11 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Craig M. Kessler it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Craig M. Kessler accepts the following insurance:

  •  Ambetter
  •  CareFirst

Call to see if your plan is accepted.
Locations
3800 Reservoir Rd Nw, Washington, DC 20007
Background & Education
Graduate Institution
Tulane University School Of Medicine, 1973
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in DC
Hospital Affiliations
MedStar Georgetown University Hospital
Sibley Memorial Hospital
Suburban Hospital
Languages Spoken
English
French
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


11 Clinical Trials

An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Research Tissue Bank
Molecular Biology of Familial Myeloproliferative Disorders
Biomarkers Serum Collection Methodology Pilot Study
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
View 10 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors